Publications, Pharmaceutical

Improving Intranasal Sprays for Respiratory Viral Infections

Intranasal sprays have considerable potential for the treatment of viral infections such as the SARS-CoV-2 virus which enter via the upper airway.

Download Publication on intranasal sprays for respiratory viral infections
28 Jan 2022

This paper describes work to improve the targeting of drug delivery for such infections by modifying intranasal spray usage protocols. Computational fluid dynamic studies and experimental validation work show that with an improved protocol, involving more shallowed (almost horizontal) angling of the intranasal spray, drug delivery to the nasopharyngeal viral infection ‘hot spot’ can be doubled. The optimal droplet size for drug delivery for such applications is discussed, and the robustness of the developed protocol is highlighted, with respect to the consistency of drug delivery.

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More

This Might Also Be of Interest

5 Jan 2023

Case Study – Unidose Nasal Spray Pump for Epilepsy

Case Studies, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
14 Dec 2022

Building Digital Solutions To Meet The Unique Therapeutic Needs of Patients

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations

Read More
30 Nov 2022

Drug Repositioning – Benefits and Challenges for Lifecycle Management

Webinars, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
24 Nov 2022

Step to Success in Nose-to-Brain Drug Delivery

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
1 8 9 10 11 12 27

Request Access

Close

Requesting access to Improving Intranasal Sprays for Respiratory Viral Infections.

  • This field is for validation purposes and should be left unchanged.
Back To Top